Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Mixed Phenotype Acute Leukemia”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)WithdrawnNCT03739606
What this trial is testing

Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer

Who this might be right for
Acute Biphenotypic LeukemiaAcute LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 Positive+12 more
City of Hope Medical Center
Testing effectiveness (Phase 2)Ended earlyNCT03404193
What this trial is testing

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeBlastic Plasmacytoid Dendritic Cell Neoplasm+12 more
M.D. Anderson Cancer Center 235
Early research (Phase 1)Study completedNCT01319864
What this trial is testing

POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients

Who this might be right for
Relapsed/Refractory AMLRelapsed/Refractory ALLSecondary AML/MDS+3 more
Seattle Children's Hospital 20
Early research (Phase 1)Looking for participantsNCT04375631
What this trial is testing

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Who this might be right for
Recurrent Acute Myeloid LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic Syndrome+6 more
Fred Hutchinson Cancer Center 120
Early research (Phase 1)Active Not RecruitingNCT05146739
What this trial is testing

Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane

Who this might be right for
Acute Myeloid Leukemia Post Cytotoxic TherapyMyelodysplastic Syndrome Post Cytotoxic TherapyMyeloid Leukemia Associated With Down Syndrome+6 more
National Cancer Institute (NCI)
Early research (Phase 1)WithdrawnNCT03807063
What this trial is testing

Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant

Who this might be right for
Acute Bilineal LeukemiaMyelodysplastic/Myeloproliferative NeoplasmMyelodysplastic/Myeloproliferative Neoplasm, Unclassifiable+9 more
Fred Hutchinson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT01858740
What this trial is testing

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children

Who this might be right for
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Biphenotypic LeukemiaAcute Leukemia of Ambiguous Lineage+15 more
Fred Hutchinson Cancer Center 20
Early research (Phase 1)Looking for participantsNCT05292664
What this trial is testing

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Who this might be right for
Myelodysplastic Syndromes, de NovoMyelodysplastic Syndromes, SecondaryMyelodysplastic Syndromes, Previously Treated+8 more
Andrew E. Place, MD 30
Early research (Phase 1)UnknownNCT01619761
What this trial is testing

NK Cells in Cord Blood Transplantation

Who this might be right for
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Biphenotypic LeukemiaAcute Lymphoblastic Leukemia in Remission+22 more
M.D. Anderson Cancer Center 13
Testing effectiveness (Phase 2)Looking for participantsNCT03128034
What this trial is testing

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

Who this might be right for
Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia+9 more
Fred Hutchinson Cancer Center 75
Testing effectiveness (Phase 2)Active Not RecruitingNCT04975919
What this trial is testing

Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Recurrent Acute Biphenotypic LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Biphenotypic Leukemia+1 more
M.D. Anderson Cancer Center 20
Testing effectiveness (Phase 2)Looking for participantsNCT03670966
What this trial is testing

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Who this might be right for
Acute Lymphoblastic Leukemia in RemissionAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia in Remission+9 more
Fred Hutchinson Cancer Center 30
Early research (Phase 1)Active Not RecruitingNCT02159495
What this trial is testing

Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

Who this might be right for
Adult Acute Myeloid Leukemia in RemissionAcute Biphenotypic LeukemiaEarly Relapse of Acute Myeloid Leukemia+10 more
City of Hope Medical Center 31
Testing effectiveness (Phase 2)Looking for participantsNCT02115295
What this trial is testing

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Who this might be right for
Acute Biphenotypic LeukemiaAcute Myeloid LeukemiaBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+11 more
M.D. Anderson Cancer Center 508
Not applicableStudy completedNCT02551718
What this trial is testing

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

Who this might be right for
Recurrent Acute Leukemia of Ambiguous LineageRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid Leukemia+3 more
University of Washington 34
Testing effectiveness (Phase 2)Study completedNCT02397720
What this trial is testing

Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia

Who this might be right for
Acute Bilineal LeukemiaAcute Biphenotypic LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome+6 more
M.D. Anderson Cancer Center 150
Testing effectiveness (Phase 2)Ended earlyNCT04874194
What this trial is testing

Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1

Who this might be right for
Hematopoietic and Lymphoid Cell NeoplasmRecurrent Acute Biphenotypic LeukemiaRecurrent Acute Myeloid Leukemia+4 more
M.D. Anderson Cancer Center 24
Very early researchStudy completedNCT03957915
What this trial is testing

Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia

Who this might be right for
Acute Lymphoblastic Leukemia RecurrentAcute Lymphoblastic Leukemia, in RelapseAcute Myeloid Leukemia, in Relapse+2 more
Institut Paoli-Calmettes 33
Testing effectiveness (Phase 2)Looking for participantsNCT02727803
What this trial is testing

Personalized NK Cell Therapy in CBT

Who this might be right for
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Biphenotypic LeukemiaAcute Lymphoblastic Leukemia+23 more
M.D. Anderson Cancer Center 100
Testing effectiveness (Phase 2)Study completedNCT02044796
What this trial is testing

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Who this might be right for
Acute Biphenotypic Leukemiade Novo Myelodysplastic SyndromePreviously Treated Myelodysplastic Syndrome+3 more
Fred Hutchinson Cancer Center 199
Next Page
8